Peritoneal Cancer - Pipeline Insight, 2022

Peritoneal Cancer - Pipeline Insight, 2022

DelveInsight’s, “Peritoneal cancer – Pipeline Insight, 2022,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Peritoneal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Peritoneal cancer Understanding

Peritoneal cancer: Overview

The peritoneum is a membrane that covers the inner lining of the abdominal cavity and the organs lying in there. It helps to support these organs and contains the blood vessels and nerves that supply them. The space in the abdominal cavity covered by the peritoneum is known as the peritoneal cavity. Peritoneal metastases refer to cancer that has spread to the peritoneum from other organs. When cancer spreads from other organs, it is considered advanced and denote Stage IV disease in most cases. Complications related to peritoneal metastases include: Ascites: Peritoneal metastases tend to produce fluid in the abdomen, known as ascites, which causes abdominal distension, Intestinal obstruction: Peritoneal metastases may cause blockage of the intestines, Hydronephrosis: The kidney ureters may be blocked by peritoneal metastases. This may affect the kidney function. The diagnosis of peritoneal cancer can be difficult. Imaging (such as CT or MRI scans), needle drainage of ascitic fluid for analysis, keyhole surgery, or a combination of these may be required to confirm the diagnosis of peritoneal metastases. Treatment of peritoneal cancer depends on the stage of cancer, where the primary tumor started, how far it has spread, and the patient’s overall health. Surgery, chemotherapy, radiotherapy, and targeted therapy.

""Peritoneal cancer - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal cancer pipeline landscape is provided which includes the disease overview and Peritoneal cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal cancer.

Peritoneal cancer Emerging Drugs Chapters

This segment of the Peritoneal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal cancer Emerging Drugs

Mirvetuximab soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The drug is being studied in phase III stage of development for the treatment of patients with peritoneal cancer.

Pembrolizumab: Merck & Co

Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. Currently it is being evaluated in Phase III stage of development for the treatment of peritoneal cancer.

PF-06873600: Pfizer

PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. The drug is being investigated in Phase II stage of development for the treatment of peritoneal cancer, HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, and Fallopian Tube Cancer.

Further product details are provided in the report……..

Peritoneal cancer: Therapeutic Assessment

This segment of the report provides insights about the different Peritoneal cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peritoneal cancer

There are approx. 55+ key companies which are developing the therapies for Peritoneal cancer. The companies which have their Peritoneal cancer drug candidates in the most advanced stage, i.e. Phase III include, ImmunoGen.

Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Peritoneal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal cancer drugs.

Peritoneal cancer Report Insights

Peritoneal cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Peritoneal cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Peritoneal cancer drugs?

How many Peritoneal cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peritoneal cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Peritoneal cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

•ImmunoVaccine Technologies, Inc. (IMV Inc.)

•ImmunoGen

•Merck & Co

•Pfizer

•Novartis Pharmaceuticals

•Imunon

•Pfizer

•AbbVie

•Astex Pharmaceuticals, Inc.

•ImmunoGen, Inc.

Key Products

•Mirvetuximab soravtansine

•PF-06873600

•Pembrolizumab

•DPX-Survivac

•Pazopanib

•GEN-1

•MEK162

•Veliparib

•Guadecitabine

•IMGN151